The estimated Net Worth of Biopharma, Inc. Aeon is at least $286 Million dollars as of 3 June 2019. Biopharma Aeon owns over 1,298,701 units of Evolus Inc stock worth over $132,274,023 and over the last 7 years Biopharma sold EOLS stock worth over $154,012,271.
Sign up
Biopharma Aeon EOLS stock SEC Form 4 insiders trading
Biopharma has made over 4 trades of the Evolus Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Biopharma sold 1,298,701 units of EOLS stock worth $24,999,994 on 3 June 2019.
The largest trade Biopharma's ever made was selling 5,307,940 units of Evolus Inc stock on 20 May 2019 worth over $102,177,845. On average, Biopharma trades about 1,363,422 units every 53 days since 2018. As of 3 June 2019 Biopharma still owns at least 8,662,346 units of Evolus Inc stock.
You can see the complete history of Biopharma Aeon stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Biopharma Aeon's mailing address?
Biopharma's mailing address filed with the SEC is 17901 Von Karman Ave #150, Irvine, CA 92614, USA.
Insiders trading at Evolus Inc
Over the last 7 years, insiders at Evolus Inc have traded over $244,915,132 worth of Evolus Inc stock and bought 3,308,677 units worth $53,545,237 . The most active insiders traders include Biopharma, Inc. Aeon, Inc. Medytox, and 1 Llc Alphaeon. On average, Evolus Inc executives and independent directors trade stock every 25 days with the average trade being worth of $3,606,270. The most recent stock trade was executed by Sandra Beaver on 6 September 2024, trading 3,276 units of EOLS stock currently worth $49,074.
What does Evolus Inc do?
evolus, inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the united states. it offers jeuveau, a proprietary 900 kilodalton purified botulinum toxin type a formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. the company was founded in 2012 and is headquartered in newport beach, california.
What does Evolus Inc's logo look like?
Complete history of Biopharma Aeon stock trades at Evolus Inc
Evolus Inc executives and stock owners
Evolus Inc executives and other stock owners filed with the SEC include:
-
Michael Jafar,
Chief Commercial Officer -
David Moatazedi,
President, Chief Executive Officer, Director -
Rui Avelar,
Chief Medical Officer, Head of Research & Development -
David Moatazedi,
Pres, CEO & Director -
Lauren Silvernail,
Chief Financial Officer, Executive Vice President - Corporate Development -
Lauren P. Silvernail,
CFO & Exec. VP of Corp. Devel. -
Dr. Rui Avelar Dip.SportMed, M.D., C.CFP,
Chief Medical Officer and Head of R&D -
Karah Parschauer,
Independent Director -
Peter Farrell,
Independent Director -
Vikram Malik,
Chairman of the Board -
David Gill,
Independent Director -
Robert Hayman,
Independent Director -
Simone Blank,
Director -
Tram Bui,
IR Contact Officer -
Jeff Plumer,
General Counsel -
Jessica Novak,
Sr. VP of HR -
Crystal Muilenburg,
Chief Marketing Officer -
Kurt Knab,
VP of Sales -
Jeffrey J. Plumer,
Gen. Counsel -
David K. Erickson,
VP of Investor Relations -
Biopharma, Inc. Aeon,
-
Sandra Beaver,
Chief Financial Officer -
Crystal Muilenburg,
Chief Marketing Officer -
Albert G Iii White,
Director -
Kristine Romine,
Director -
Bosun Hau,
Director -
1 Llc Alphaeon,
-
Brady Stewart,
Director -
Tomoko Yamagishi Dressler,
Chief Marketing Officer -
Inc. Medytox,